> 65 years
Lung cancer mainly occurs in men >65 years of age. The average age when the cancer is diagnosed is 70 years.1
3rd in Europe
Lung cancer is the third most common cancer in Europe; NSCLC is the largest subtype (85%–90%).5
Lung tumours subtypes and use of cryoablation
1. Non-small cell lung cancer (NSCLC)
Lung adenocarcinoma starts in mucus-producing glandular cells, and it often develops in smaller airways, such as the alveoli. It is more common in women and young people (20-46). C
Incidence (per 100,000 per year): 17.9 A (40% of all lung cancers) B
Use of cryoablation:
Recent studies report percutaneous image-guided cryoablation of lung cancer as a minimally invasive procedure that is a particularly effective curative treatment of medically inoperable early-stage lung cancer and for tumour debulking in advanced-stage lung carcinoma.I, L
The safety and the effectiveness of the cryoablation procedure to treat central lung tumours (primary and secondary) have been proven in multiple studies.K, L
It has been demonstrated that the treatment of patients with stage IIIB/IV NSCLC with cryoablation has the advantage of decreased intra-procedural pain compared with microwave ablation.M
Squamous cell carcinoma (SCC) usually develops in the flat cells that cover the medium-large airways, close to the lung’s centre. It is more often associated with smoking than other types of NSCLS.E, F
Incidence (per 100,000 per year): 13.3 A (25–30% of all lung cancers)B
Use of cryoablation:
Recent studies report percutaneous image-guided cryoablation of lung cancer as a minimally invasive procedure that is a particularly effective curative treatment of medically inoperable early-stage lung cancer and for tumour debulking in advanced-stage lung carcinoma.I, L
The safety and the effectiveness of the cryoablation procedure to treat central lung tumours (primary and secondary) have been proven in multiple studies.K, L
It has been demonstrated that the treatment of patients with stage IIIB/IV NSCLC with cryoablation has the advantage of decreased intra-procedural pain compared with microwave ablation.M
Large cell carcinoma is a rare type of cancer that can appear in different areas of the lung, usually in the periphery. It generally tends to grow and spread quickly. It is more common in men.G
Incidence (per 100,000 per year): 3.1 A (10–15% of all lung cancers)B
Use of cryoablation:
Recent studies report percutaneous image-guided cryoablation of lung cancer as a minimally invasive procedure that is a particularly effective curative treatment of medically inoperable early-stage lung cancer and for tumour debulking in advanced-stage lung carcinoma.I, L
The safety and the effectiveness of the cryoablation procedure to treat central lung tumours (primary and secondary) have been proven in multiple studies.K, L
It has been demonstrated that the treatment of patients with stage IIIB/IV NSCLC with cryoablation has the advantage of decreased intra-procedural pain compared with microwave ablation.M
2. Small cell lung cancer (SCLC)
Small cell lung cancer develops in the bronchi of greater diameter, is made up of small cells and usually occurs in smokers; it is very rare in those who have never smoked. It is a very aggressive cancer that tends to spread rapidly. H
Incidence (per 100,000 per year): 6.0 A (10% to 15% of all lung cancers)D
Use of cryoablation:
A case study reports the effective use of the cryoablation treatment, combined with low-dose chemotherapy, to treat a patient with unresectable small cell lung cancer. The procedure made it possible to have more than 7 years of survival and a great quality of life for the patient.N
Treatment options
There are a number of treatment options for lung cancer. The therapeutic approach varies according to the patient's condition, the stage of the cancer, the molecular characteristics, and, above all, the histology of the tumour.
The most common treatments for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), are6:
- Surgery
- Radiation therapy
- Chemotherapy
- Immunotherapy
- Laser therapy
- Cryoablation
Clinical results – why cryoablation?
Discover cryoablation for lung tumours
- Filename
- PI-883803-AA Cryoablation Case Study- Lungs 57yrs De Baere- FINAL.pdf
- Size
- 1 MB
- Format
- application/pdf
67.8%
5-year overall survival
1.6 days
Short hospital stay
Cryoablation has been demonstrated to be safe in the treatment of lung tumours and a viable alternative to surgery for certain patients. This procedure has not only been shown to effectively maintain pulmonary functions, but it also provides good overall long-term survival (5-year overall survival: 67.8%)7 for patients, with minimal complications and short hospital stay (1.6 days).7
Discover cryoablation for metastatic lung tumours
ECLIPSE multicentre study: Cryoablation for the treatment of metastatic lung tumours
78.2%
Free from local progression at 5 years10
79.2%
(per tumour) & 75% (per patients) local control rates at 5 years10
According to the American Lung Association (ALA), the overall 5-year survival rate for patients with metastatic lung tumours is 18.6%.9
The recent ECLIPSE Study has shown that cryoablation is an effective treatment for metastatic lung tumours, providing long-term tumour control (79.2% at 5 years) and good survival rate (46.7% at 5 years).10
SOLSTICE multicentre study: Cryoablation for the treatment of metastatic lung tumours
97.6%
Overall survival (12 months)12
84%
Secondary treatment efficacy (2 years)12
85%
Local recurrence-free survival (12 months)12
Metastatic lung tumours have a major impact on patients, representing a life-threatening condition that can be hard to treat successfully.11
The recent SOLSTICE Multicentre Study of metastatic lung tumours has demonstrated that percutaneous cryoablation is a safe and effective treatment for pulmonary metastases which results in a high rate of survival (86.6%/24 months).12
Our cryoablation solutions
We offer a broad portfolio of cryoablation systems and needles that provide an efficient treatment against tumours
With game-changing innovation, we’ve streamlined our technology to meet the practical and efficiency demands of your minimally invasive procedures with no compromise to performance.
References:
1. Key Statistics for Lung Cancer, Cancer.org. Last Revised: January 12, 2021. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
2. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2018) 29(Suppl 4): iv192–iv237. doi: 10.1093/annonc/mdy275
3. Eldridge L. Primary and Secondary Lung Cancer, Verywellhealth.com. Updated on April 13, 2021. https://www.verywellhealth.com/what-is-primary-lung-cancer-2249409#primary-lung-cancer
4. What is Lung Cancer?, Cancer.org. Last Revised: October 1, 2019. https://www.cancer.org/cancer/lung-cancer/about/what-is.html
5. Planchard D, Novello S, Peters S, et al. Non-Small-Cell Lung Cancer: an ESMO guide for patients. 2019. https://www.esmo.org/content/download/7252/143219/1/EN-Non-Small-Cell-Lung-Cancer-Guide-for-Patients.pdf
6. Types of Lung Cancer, lungevity.org. Updated March 2, 2021. https://www.lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer/small-cell-lung-cancer-sclc
7. Moore W, Talati R, Bhattacharji P, et al. Five-Year Survival after Cryoablation of Stage 1 Non-Small Cell Lung Cancer in Medically Inoperable Patients. J Vasc Interv Radiol. 2015 Mar;26(3):312-9. doi: 10.1016/j.jvir.2014.12.006
8. Colak E, That S, Shyn P.B, et al. CT-guided percutaneous cryoablation of central lung tumors. Diagn Interv Radiol. 2014; 20: 316-322. doi: 10.5152/dir.2014.13440
9. Fletcher J. Life expectancy and survival rates for metastatic lung cancer. April 1, 2021. Medically reviewed by Christina Chun. https://www.medicalnewstoday.com/articles/life-expectancy-and-survival-rates-for-metastatic-lung-cancer
10. De Baère T, Woodrum D, Tselikas L, et al. The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors with a 5-Year Follow-Up. Journal of Thoracic Oncology, August 2021. doi: 10.1016/j.jtho.2021.07.021
11. Lung Metastasis, Health Encyclopedia – University of Rochester, Medical Center. 2021. https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=22&contentid=lungmetastasis
12. Callstrom M.R, Woodrum D.A, Nichols F.C, et al. Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE). J Thorac Oncol. 2020 Jul;15(7):1200-1209. doi: 10.1016/j.jtho.2020.02.022
A. Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, Yin J, Zhan C, Wang Q. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943-953. doi: 10.2147/CMAR.S187317
B. Planchard D, Novello S, et al. 2019. See note n. 5.
C. Lung Adenocarcinoma, lungevity.org. Updated February 10, 2021. https://www.lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer/lung-adenocarcinoma
D. What is Lung Cancer? - Cancer.org. 2019. See note n. 4.
E. Types of Lung Cancer, Cancer Research UK. Last reviewed: January 28, 2020. https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types-grades/types
F. Squamous Cell Lung Cancer, lungevity.org. Updated February 12, 2021. https://www.lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer/squamous-cell-lung-cancer
G. Large Cell Lung Cancer, lungevity.org. Updated February 12, 2021. https://www.lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer/large-cell-lung-cancer
H. Small cell lung cancer (SCLC), longevity.org. Updated March 2, 2021. https://www.lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer/small-cell-lung-cancer-sclc
I. Zhang Y-S, Niu L-Z, Li Z-H, et al. Percutaneous imaging-guided cryoablation for lung cancer. J Thorac Dis. 2016 Oct; 8(Suppl 9): S705–S709. doi: 10.21037/jtd.2016.09.42
J. Inoue M, Nakatsuka S, Jinzaki M. Cryoablation of early-stage primary lung cancer. Biomed Res Int. 2014;2014:521691. doi: 10.1155/2014/521691
K. Colak E, Tatli S, Shyn P.B, et al. CT-guided percutaneous cryoablation of central lung tumors. Diagn Interv Radiol. 2014 Jul-Aug; 20(4): 316–322. doi: 10.5152%2Fdir.2014.13440
L. Pusceddu C, Sotgia B, Fele R.M, Melis L. CT-guided thin needles percutaneous cryoablation (PCA) in patients with primary and secondary lung tumors: a preliminary experience. Eur J Radiol. 2013 May;82(5):e246-53. doi: 10.1016/j.ejrad.2012.12.010 M. Kumar Das S, Huang Y-Y, Li B, et al. Comparing cryoablation and microwave ablation for the treatment of patients with stage IIIB/IV non-small cell lung cancer. Oncol Lett. 2020 Jan;19(1):1031-1041. doi: 10.3892/ol.2019.11149
N. Li Q, Zhou T, Jiang M, et al. A case of unresectable small cell lung cancer more than 7 years of survival treated with cryoablation and low dose chemotherapy. Integr Cancer Sci Therap. Volume 2(5): 222-225. 2015. doi: 10.15761/ICST.1000145
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.